KLK3 and prostate carcinoma: In addition to its differentiating properties in prostate cancer cell lines, calcitriol has been shown to inhibit the growth, reduce invasion and angiogenesis, stimulate apoptosis and is synergistic with chemotherapy.[18] In an interim report of the phase III ASCENT (AIPC study of enhancing taxotere) trial, while the primary endpoint of PSA response was not met, there was an intriguing improvement in overall survival, although it must be emphasized that further follow-up will be critical to the interpretation of these data.[19]